Open-label extension treatment with TNFR:Fc [etanercept] for participating patients in TNFR:Fc clinical trial 016.0012.
Phase of Trial: Phase III
Latest Information Update: 13 May 2013
At a glance
- Drugs Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 25 Aug 2009 Actual patient number (468) added as reported by ClinicalTrials.gov.
- 11 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.